IBA’s management team will host team will host a conference call and webcast conducted in English to present the half year results, followed by a Q&A session. The conference call will be held on ...

The Hemp Doctor introduces the Fresh Bloom THCA Flower Subscription Box, a monthly drop of hand-selected flower and pre-rolls ...

On March 12, 2026, Novonesis, through Novozymes A/S, successfully priced and closed an aggregate principal amount of EUR 1.7 billion senior unsecured notes (the "Notes"). The issuance was completed ...

Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) ...

The notes will be senior, unsecured obligations of Indivior and will accrue interest at a rate of 0.625% per annum, payable semi-annually in arrears on March 15 and September 15 of each year, ...

BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its financial results for the fourth quarter and full year ended December 31, 2025 on Thursday, March 19, 2026 after market ...

On November 13, 2025, the Company announced additional 52-week follow-up data from the RESOLVE trial in eosinophilic esophagitis (“EoE”) demonstrating consistent results after dosing with EP-104GI.

NervGen Pharma Corp. (“NervGen” or the “Company") (TSXV: NGEN) (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury ...

DigitalOptometrics (DO), the leading provider of tele-optometry and remote ophthalmic care solutions, today announced the next major evolution of its platform at Vision Expo East, further advancing ...

The Ensign Group, Inc. (Nasdaq: ENSG), the parent company of the Ensign ™ group of companies, which invest in and ...

No published clinical trial appears to have evaluated GlycoPezil as a proprietary formula. If you've been researching blood sugar support supplements lately, GlycoPezil is likely one of the names ...

Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including ...